{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A465", "status": "success", "status_code": 200, "timestamp_elapsed": 0.004249, "timestamp_received": "2026-09-25T00:13:56.923699+00:00Z", "timestamp_returned": "2026-09-25T00:13:56.927948+00:00Z", "trace_id": "79374325-1bd9-4b28-b7b4-fdb4e41d530f" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:rybrevant:3:0", "type": "Statement", "description": "The U.S. Food and Drug administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2024-09-19:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2024-09-19", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:rybrevant", "type": "Document", "documentType": "Regulatory approval", "name": "Rybrevant (amivantamab-vmjw) [package insert]. FDA.", "title": null, "aliases": [], "description": "Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Janssen Biotech, Inc.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Rybrevant", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "amivantamab-vmjw", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2021-05-21", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 761210, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-09-19", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:465", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:NSCLC", "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC" ] } }, "objectTherapeutic": { "id": "txgrp:6", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C1282", "conceptType": "Therapy", "name": "Carboplatin", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:40048", "code": "40048", "name": "carboplatin", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=40048" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4299846", "code": "4299846", "name": "Carboplatin", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4299846" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:386905002", "code": "386905002", "name": "Carboplatin", "system": "SNOMED", "systemVersion": "2026-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=386905002&edition=MAIN/2026-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1344905", "code": "1344905", "name": "carboplatin", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1344905" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Platinum-based chemotherapy" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282" ] } }, { "id": "tx:ncit:C61614", "conceptType": "Therapy", "name": "Pemetrexed", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:68446", "code": "68446", "name": "pemetrexed", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=68446" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1304919", "code": "1304919", "name": "pemetrexed", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1304919" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:409159000", "code": "409159000", "name": "Pemetrexed", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=409159000&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4247743", "code": "4247743", "name": "Pemetrexed", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4247743" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Antifolate" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614" ] } }, { "id": "tx:ncit:C124993", "conceptType": "Therapy", "name": "Amivantamab", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2549199", "code": "2549199", "name": "amivantamab", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2549199" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1536935", "code": "1536935", "name": "amivantamab", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1536935" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:1162751008", "code": "1162751008", "name": "Amivantamab", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=1162751008&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:37160574", "code": "37160574", "name": "Amivantamab", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/37160574" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "EGFR inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C124993", "code": "C124993", "name": "Amivantamab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:10", "present": true, "subject": { "id": "bmkr:10", "type": "CategoricalVariant", "name": "EGFR Exon 19 (Deletion)", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.d2mE9fs239Iqh2Rx3pBVNl0txu4dXxDT", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence within refseq:NP_005219.2, the protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to Exon 19.", "digest": "d2mE9fs239Iqh2Rx3pBVNl0txu4dXxDT", "sequenceReference": { "id": "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "type": "SequenceReference", "name": "NP_005219.2", "aliases": [ "ensembl:ENSP00000275493.2", "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "refseq:NP_005219.2" ], "description": "The protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to the Refseq protein accession NP_005219.2.", "moleculeType": "protein", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "residueAlphabet": "aa" }, "start": 728, "end": 761, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:3236", "conceptType": "Gene", "name": "EGFR", "primaryCoding": { "id": "coding:hgnc:3236", "code": "HGNC:3236", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000146648", "code": "ENSG00000146648", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000146648" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:1956", "code": "1956", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/1956" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005228.5", "code": "NM_005228.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "7" }, { "name": "start_position", "value": null }, { "name": "end_position", "value": null }, { "name": "reference_allele", "value": null }, { "name": "alternate_allele", "value": null }, { "name": "cdna_change", "value": null }, { "name": "protein_change", "value": null }, { "name": "variant_annotation", "value": "Deletion" }, { "name": "exon", "value": 19 }, { "name": "rsid", "value": null }, { "name": "hgvsg", "value": null }, { "name": "hgvsc", "value": null }, { "name": "requires_oncogenic", "value": true } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:rybrevant:3", "type": "Indication", "description": "RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2024-09-19:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2024-09-19", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:rybrevant", "type": "Document", "documentType": "Regulatory approval", "name": "Rybrevant (amivantamab-vmjw) [package insert]. FDA.", "title": null, "aliases": [], "description": "Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Janssen Biotech, Inc.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Rybrevant", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "amivantamab-vmjw", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2021-05-21", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 761210, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-09-19", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }